Effects of recombinant Recombinant luteinizing hormone (rLH) on the outcome of assisted reproductive technology

Comparison the results of adding Recombinant luteinizing hormone (rLH) to Recombinant folicle stimulating hormone (r-FSH) with r-FSH alone on pregnancy rate in normoresponder infertile patients in assisted reproductive technolog treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201304302575N4

Enrollment

Registered

2013-10-07

Start date

2013-03-20

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

infertility. Habitual aborter, Female infertility, Complications associated with artificial fertilization

Interventions

Intervention 1: group1(intervention): Patients undergoe pituitary down-regulation with Buserelin(Cinnafact®, Laboratory, Cinnagen, Iran) using a daily dose of 500 mg, s.c., according to the long agoni

Luveris®, LaboratoiresSerono S.A.) , 75 IU s.c., adding FSH for a maximum of 10 days. Intervention 2: group2(control): Patients underwent pituitary down-regulation with Buserelin using a daily dose of

Treatment - Drugs

group1(intervention): Patients undergoe pituitary down-regulation with Buserelin(Cinnafact®, Laboratory, Cinnagen, Iran) using a daily dose of 500 mg, s.c., according to the long agonist protocol, sta

Luveris®, LaboratoiresSerono S.A.) , 75 IU s.c., adding FSH for a maximum of 10 days..

group2(control): Patients underwent pituitary down-regulation with Buserelin using a daily dose of 500 mg, s.c., according to the long agonist protocol, starting on day 21 of the cycle preceding gonad

Eligibility

Sex/Gender

Female

Age

26 Years to 35 Years

Inclusion criteria

Inclusion criteria: inclusion criteria: infertile women younger than 35 years, serum day 3 Folicle stimulating hormone (FSH) levels <10, male infertility or unexplained infertility and body mass index (BMI) less than 30. exclusion criteria: azoospermia, uterine myoma, mild endometriosis, Hydrosalpinx, history of previous In vitrofertilization (IVF) (successful or unsuccessful), history of endocrine diseases such as diabetes or thyroid disorders and patients who had hysteroscopic surgery due to intrauterine lesions such as uterine sub-mucosal myoma or intrauterine adhesions

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pregnancy rate. Timepoint: one time, after intevention. Method of measurement: B hCG levels.	—

Countries

Iran (Islamic Republic of)

Contacts

Public Contactfereshteh mohseni

Yazd research and clinical center for infertility

fereshtehmohseni73@gmail.com+98 915 341 6951

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026